This paper is marked retracted in the scholarly record (OpenAlex). Interpret its findings with caution.
Retraction: Rhodomyrtus tomentosa as a new anticancer molecular strategy in breast histology via Her2, IL33, EGFR, and MUC1
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsNatural Compound Pharmacology Studies · Biological and pharmacological studies of plants · Bioactive Natural Diterpenoids Research
The Journal retracts the 2024 article cited above.
Following publication, concerns were raised regarding the integrity of the images in the published figures on PubPeer, where several partial duplications across Figures 5–8 are documented.
The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers’ policies. As a result, the data and conclusions of the article have been deemed unreliable, and the article has been retracted.
This retraction was approved by the Chief Executive Editor of Frontiers. The authors do not agree to this retraction.
Frontiers would like to thank Sholto David for contacting the journal regarding the published article.